Epics Therapeutics
Manufacturing · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Adrienne Bolland 47, Gosselies, Wallonia...Phone Number
+32 71348500Website
www.epicstherapeutics.comRevenue
$6.1 MillionIndustry
ZI Rank: 1
About Epics Therapeutics
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Epics Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Epics Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Epics Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Epics Therapeutics is spiking on competitors!
Click to see if Epics Therapeutics had a recent Job posting/layoffs
Epics Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Epics Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Epics Therapeutics
Funding: Get notified immidiatlly once Epics Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Epics Therapeutics Tech Stack
A closer look at the technologies used by Epics Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Epics Therapeutics
EPICS Therapeutics is a clinical-stage biotechnology company that specializes in developing small-molecule modulators of RNA epigenetics, with a focus on cancer treatment. Their lead program, EP102, is a METTL3 inhibitor currently in clinical evaluation for patients with solid tumors. The company aims to address unmet needs in cancer therapy by tar... Read More
